Afatinib: all 164 studies that test it
Page 2 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Afatinib in Advanced NRG1-Rearranged MalignanciesCompletedNCT04410653Phase 2
- Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaCompletedNCT04201756Phase 2
- A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneStatus unknownNCT04158947Phase 2
- To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive MutationStatus unknownNCT04132102Phase 4
- Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Status unknownNCT03940976Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung CarcinomaStatus unknownNCT03827070Phase 1
- An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 MutationStatus unknownNCT03810872Phase 2
- Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung CancerCompletedNCT03727724Phase 2
- Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLCTerminatedNCT03711422Phase 1
- Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)CompletedNCT03695510Phase 2
- Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03652233Phase 1
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
- Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell CarcinomaStatus unknownNCT03486509Phase 2
- Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the EndometriosisWithdrawnNCT03481842Phase 1/2
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
- Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
- Afatinib in Locally Advanced and Metastatic ChordomaCompletedNCT03083678Phase 2
- Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT03054038Phase 1
- Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic CancerStatus unknownNCT02975141Phase 1
- Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor ComplexWithdrawnNCT02876081Phase 2
- Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or GefitinibCompletedNCT02747953Phase 2
- Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNACompletedNCT02629523Phase 2
- Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLCCompletedNCT02625168Phase 2
- Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)TerminatedNCT02595840Phase 2
- Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of AfatinibStatus unknownNCT02511847Phase 2
- A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER GeneCompletedNCT02506517Phase 2
- Afatinib, Paclitaxel, 2nd Line, Advanced Gastric CancerCompletedNCT02501603Phase 2
- Maintaining ERBB Blockade in EGFR-mutated Lung CancerTerminatedNCT02488694Phase 2
- Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.SuspendedNCT02470065Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary CancerCompletedNCT02451553Phase 1
- Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerStatus unknownNCT02450656Phase 1/2
- Safety Study of Afatinib for Brain CancerCompletedNCT02423525Phase 1
- A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of EsophagusStatus unknownNCT02353936Phase 2
- Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line TreatmentWithdrawnNCT02274012Phase 2
- Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction ChemotherapyCompletedNCT02216617Phase 1
- Deciphering Afatinib Response and Resistance With INtratumour HeterogeneityCompletedNCT02183883Phase 2
- Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male VolunteersCompletedNCT02171767Phase 1
- Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171741Phase 1
- Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171728Phase 1
- BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male VolunteersCompletedNCT02171715Phase 1
- Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumoursCompletedNCT02171702Phase 1
- Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male VolunteersCompletedNCT02171689Phase 1
- BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171676Phase 1
- Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171663Phase 1
- BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171650Phase 1
- Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171637Phase 1
- Afatinib Plus Nimotuzumb for NSCLCStatus unknownNCT01861223Phase 1/2
- Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive ChemoradiationWithdrawnNCT01836341Phase 1
- Adjuvant Afatinib in Stage I-III NSCLC With EGFR MutationStatus unknownNCT01746251Phase 2
- Afatinib as Cancer Therapy for Exocrine Pancreatic TumoursStatus unknownNCT01728818Phase 2
- Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing ChemotherapyCompletedNCT01594177Phase 2
- Afatinib With CT and RT for EGFR-Mutant NSCLCActive, not recruitingNCT01553942Phase 2
- Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung CancerCompletedNCT01542437Phase 2
- Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and NeckCompletedNCT01538381Phase 2
- BIBW 2992 (Afatinib) and VinorelbineTerminatedNCT01531764Phase 2
- A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT01480141Phase 2
- Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and NeckCompletedNCT01427478Phase 3
- Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC PatientsCompletedNCT01415674Phase 2
- Efficacy and Safety Study of Afatinib to Treat Lung Cancer PatientsCompletedNCT01415011Phase 2
- BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate CancerTerminatedNCT01320280Phase 2
- A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal CancerCompletedNCT00801294Phase 2
- Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid TumorsCompletedNCT00730821Phase 1